EUCAST Technical note on Amphotericin B

被引：27

作者：

Lass-Floerl, C. ^{[1
]}

Arendrup, M. C. ^{[2
]}

Rodriguez-Tudela, J. -L. ^{[3
]}

Cuenca-Estrella, M. ^{[3
]}

Donnelly, P. ^{[4
,5
]}

Hope, W. ^{[6
]}

机构：

[1] Innsbruck Med Univ, Div Hyg & Med Microbiol, A-6020 Innsbruck, Austria

[2] Statens Serum Inst, Unit Mycol, Dept Mictobiol Surveillance & Res, DK-2300 Copenhagen, Denmark

[3] Inst Salud Carlos III, Mycol Reference Lab, Natl Ctr Microbiol, Majadahonda, Spain

[4] Radboud Univ Nijmegen, Med Ctr, Dept Haematol, NL-6525 ED Nijmegen, Netherlands

[5] Radboud Univ Nijmegen, Nijmegan Univ Ctr Infect Dis, NL-6525 ED Nijmegen, Netherlands

[6] Univ Manchester, Manchester, Lancs, England

来源：

CLINICAL MICROBIOLOGY AND INFECTION | 2011年 / 17卷 / 12期

关键词：

Amphotericin B; breakpoints; EUCAST technical note; susceptibility testing;

D O I：

10.1111/j.1469-0691.2011.03644.x

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST) has determined breakpoints for amphotericin B for Candida spp. This Technical Note is based on the EUCAST amphotericin B rationale document (available on the EUCAST website: ). Species-specific breakpoints for C. albicans, C. glabrata, C. krusei, C. parapsilosis and C. tropicalis are S: MIC =1 mg/L, R: MIC > 1 mg/L. There are insufficient data to set breakpoints for other species. The breakpoints are based upon pharmacokinetic data, epidemiological cut-ff values and clinical experience. Breakpoints will be reviewed regularly.

引用

页码：E27 / E29

页数：3